The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 5, 2010, Pages 446-451

  Vaz Fragoso, Carlos A ^a,b   Concato, John ^a,b   McAvay, Gail ^a   Van Ness, Peter H ^a   Rochester, Carolyn L ^a,b   Yaggi, H Klar ^a,b   Gill, Thomas M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Chronic obstructive pulmonary disease; FEV1 FVC; Lower limit of normal; Mortality; Respiratory symptoms

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COHORT ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; GROUPS BY AGE; HUMAN; LAMBDA MU SIGMA METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPIROMETRY; UNITED STATES; AGE; CHI SQUARE DISTRIBUTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REFERENCE VALUE; SEX DIFFERENCE; VITAL CAPACITY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; SEX FACTORS; UNITED STATES; VITAL CAPACITY;

EID: 77649155751     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200909-1366OC     Document Type: Article

References (29)

1. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26: 948-968.
2. Stanojevic S,Wade A, Stocks J, Hankinson J,CoatesAL, PanH, Rosenthal M, Corey M, Lebecque P, Cole TJ. Reference ranges for spirometry across all ages. Am J Respir Crit Care Med 2008;177:253-260.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al.; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
4. Hansen JF, Sun X-G, Wasserman K. Spirometric criteria for airway obstruction. Chest 2007;131:349-355.
5. Fragoso CAV, Concato J, McAvay G, Van Ness PH, Rochester CL, Yaggi HK, Gill TM. Defining chronic obstructive pulmonary disease in older persons. Respir Med 2009;103:1468-1476.
6. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-187.
7. Joint website of Great Ormond Street Hospital for Children NHS Trust (GOSH) and UCL Institute of Child Health (ICH) [Internet]. Spirometry. London:GOSH and ICH [accessed 2009 April 24]. Available from: http://www.ich.ucl.ac.uk/ich/academicunits/growinglungs/Homepage
8. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991;144:1202-1218.
9. Pirkle JL, Bernert JT, Caudill SP, Sosnoff CS, Pechacek TF. Trends in the exposure of nonsmokers in the US population to secondhand smoke: 1988-2002. Environ Health Perspect 2006;114:853-858.
10. Celli BR, Halbert RJ, Nordyke RJ, Schau B. Airway obstruction in never smokers: results from the third national health and nutrition examination survey. Am J Med 2005;118:1364-1372.
11. Gross NJ. Chronic obstructive pulmonary disease outcome measurements. Proc Am Thorac Soc 2005;2:267-271.
12. Cherry DK, Burt CW, Woodwell DA. National ambulatory medical care survey: 1999 summary.AdvancedData fromVital andHealth Statistics; no 322. Hyattsville, MD: National Center for Health Statistics. 2001.
13. Mannino DM, Buist AS, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007;62:237-241.
14. US Department of Health and Human Services. Third National Health and Nutrition Examination Survey, 1988-94, NHANES III laboratory data file (CD-ROM); Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 1996. Available from National Technical Information Service, Springfield, VA. Public use data file documentation no. 76,200.
15. Wheatcroft G, Cox CS, Lochner KA. Comparative analysis of the NHANES III public-use and restricted-use linked mortality files [Internet]. Hyattsville, MD: National Center for Health Statistics [accessed January 12, 2010.]. Available from: http://www.cdc.gov/nchs/data-access/data-linkage/mortality/ nhanes3-linkage.htm
16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo RO, Enright P, van der Grinten CPM, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
17. Brown DW, Croft JB, Greenlund KJ, Giles WH. Deaths from chronic obstructive pulmonary disease: United States, 2000-2005. MMWR Morb Mortal Wkly Rep 2008;57:1229-1232.
18. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-1510.
19. Research Triangle Institute. SUDAAN language manual, release 9.0. Research Triangle Park, NC: Research Triangle Institute; 2004.
20. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-1450.
21. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review andmeta-analysis.JAMA2008;300:2407-2416.
22. Feinstein AR. The inadequacy of binary models for the clinical reality of three-zone diagnostic decisions. J Clin Epidemiol 1990;43:109-113.
23. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-2646.
24. Nishimura K, Tsukino M. Clinical course and prognosis of patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000;6:127-132.
25. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, and the Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005;142:233-239.
26. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002;166:333-339.
27. Vestbo J, Hansen EF. Airway hyperresponsiveness and COPD mortality. Thorax 2001;56:11-14.
28. Hansen EF, Vestbo J. Bronchodilator reversibility in COPD. Eur Respir J 2005;26:6-7.
29. Dransfield MT, Bailey WC. COPD: racial disparities in susceptibility, treatment, and outcomes. Clin Chest Med 2006;27:463-471.